Oncotype DX 2017 vs current OncotypeDX reporting

Yes, for node negative there is a difference. The TAILORx study came out in late 2018 and the Oncotype node neg. recurrence risk estimates for low to intermediate scores were adjusted to reflect the new findings.

As far as I know there is nowhere that you can input your score to have it recalculate. I do however have the results from the TAILORx study. The following chart is found in the Supplementary Appendix. https://www.nejm.org/doi/full/10.1056/NEJMoa1804710

• The top graph is for those aged 50 and under; the bottom graph is for over age 50.
• The red and blue solid lines reflect the 9-year metastatic recurrence risk estimates that are now associated with each Oncotype score.
• The solid red line reflects endocrine therapy only (either Tamoxifen or an AI) . The red line stops at a 25 score because everyone in the study with a higher score was given chemo (or they were kicked out of the study).
• The solid blue line reflects chemo + endocrine therapy. The blue line only starts at an 11 Oncotype score because no chemo was given to those with lower scores.
• The red and blue dotted lines on the chart are the high and low ranges - the solid line is the average.